PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Eplerenone - Heart failure

PAD Profile : Eplerenone - Heart failure

Brand Names Include :
Inspra

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Initiation restricted to cardiology. Transfer to primary care only after initiation and at least the first month supply from the specialist.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Eplerenone has been considered by the PCN and has been assigned a BLUE traffic light status. NOTE - the branded product, Inspra, was considered BLACK at the PCN in May 2017.
30 January 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey Heart and Stroke Network requested that the PCN reconsider their recommendations made in January 2012 where Eplerenone should be reserved for patients that cannot tolerate/ have a contraindication to spironolactone. The network members noted the license for eplerenone and concurred that it is currently licensed for patients with New York Heart Association (NYHA) Class II chronic heart failure. They concurred that spironolactone should continue to be the first line aldosterone antagonist at all stages of heart failure with eplerenone used in patients who have side effects with spironolactonee.g. gynaecomastia, or perhaps a significant fear of gynaecomastia. This would be on the basis that spironolactone has high quality, randomised controlled trial evidence of effectiveness from the RALES study in heart failure NYHA class III or IV, established data for hyperkalaemia risks, it is likely (but not known) that spironolactone would also be effective at other stages of heart failure as well as NYHA III and IV, and it has a broad licence for congestive cardiac failure which is not restricted to any heart failure class.
25 January 2012
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Spironolactone should be 1st line with eplerenone reserved for patients with NYHA class II CHF who are intolerant to/ have contraindications to spironolactone. Eplerenone should also only be initiated under the supervision of a cardiologist and as such will be considered amber*. The document will be uploaded again once the amber* document has been through internal governance processes at the actue trusts and contact details have been added.

Associated BNF Codes

02. Cardiovascular System
02.02.03. Potassium-sparing diuretics and aldosterone antagonists
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More